Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ANL

Adlai Nortye Ltd. ADR

Nov 28 • 01:25PM ET

10.67

Dollar change +0.11
Percentage change 1.04	%

Healthcare • Biotechnology • China • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	-	Perf Week	8.55%
Market Cap	-	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	31.40%
Income	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float / Ratio	- / 0.19	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Interest	0.00M	Perf Half Y	-
Book/sh	-	P/B	-	EPS next Y	-	ROA	-	Target Price	30.00	Perf Year	-
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	7.82 - 19.30	Perf YTD	-28.87%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-44.71%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	36.45%	ATR	0.55
Employees	-	Current Ratio	-	Sales Q/Q	-	Oper. Margin	-	RSI (14)	56.34	Volatility	1.92% 4.25%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.06	Prev Close	10.56
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	23.42K	Price	10.67
Recom	1.00	SMA20	17.08%	SMA50	9.35%	SMA200	9.35%	Volume	1,029	Change	1.04%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$30

Nov-17-23 07:30AM	Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC (GlobeNewswire)
Oct-23-23 08:12AM	Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award (GlobeNewswire)
Oct-03-23 12:05PM	Adlai Nortye Ltd. Announces Closing of Initial Public Offering (GlobeNewswire) -6.87%
Sep-29-23 02:46AM	Adlai Nortye Ltd. Announces Pricing of Initial Public Offering (GlobeNewswire)

Adlai Nortye Ltd. operates as a clinical-stage biopharmaceutical company focused on the development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018 and is headquartered in Hangzhou, China.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANL

Adlai Nortye Ltd. ADR

Upgrade your FINVIZ experience